The Epigenomic Signature of Eosinophilic Granulomatosis With Polyangiitis

Launched by MEYER CHILDREN'S HOSPITAL IRCCS · Jan 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a condition called Eosinophilic Granulomatosis with Polyangiitis (EGPA), which affects the blood vessels and can cause various health problems. The researchers want to learn more about specific changes in the blood that can help identify patients with EGPA and predict how well they might respond to a treatment called Mepolizumab. This study will involve analyzing blood samples from 300 patients with EGPA, comparing their results to existing data from healthy individuals. By understanding these blood markers, the goal is to improve future treatment options for EGPA patients.

To be eligible for this study, participants must be adults over 18 years old who meet specific medical criteria for EGPA. They need to provide written consent to join the study. Participants will have a blood sample taken, but there will be no changes to their usual medical care. This study is observational, meaning researchers will simply observe and collect data without altering treatment plans. It's important to note that individuals with childhood-onset EGPA or those who are pregnant or breastfeeding cannot participate. The study is not yet recruiting participants, but it aims to gather valuable information that could lead to better management of EGPA in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients over 18 years of age who meet the 1990 American College of Rheumatology classification criteria for EGPA or the criteria proposed in the MIRRA trial, or the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria;
• • Written informed consent from all the study participants.
• Exclusion Criteria:
• • Patients with inadequate or unavailable data regarding response to treatment at months 6 and 12 after Mepolizumab initiation will be included in the case-control Epigenome-Wide Association Study (EWAS) but not in the predictive epigenomic study;
• • Patients with childhood-onset EGPA;
• • Patients who are pregnant or breast-feeding.